JP7300989B2 - 核酸分子を解析するための方法およびシステム - Google Patents

核酸分子を解析するための方法およびシステム Download PDF

Info

Publication number
JP7300989B2
JP7300989B2 JP2019533331A JP2019533331A JP7300989B2 JP 7300989 B2 JP7300989 B2 JP 7300989B2 JP 2019533331 A JP2019533331 A JP 2019533331A JP 2019533331 A JP2019533331 A JP 2019533331A JP 7300989 B2 JP7300989 B2 JP 7300989B2
Authority
JP
Japan
Prior art keywords
nucleic acid
dna
nucleic acids
molecules
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019533331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504606A (ja
JP2020504606A5 (OSRAM
Inventor
アンドリュー ケネディ，
ステファニー アン ウォード モーティマー，
ヘルミー エルトーキー，
アミルアリ タラサズ，
ダイアナ アブドゥエヴァ，
マシュー シュルツ，
Original Assignee
ガーダント ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61006366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7300989(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ガーダント ヘルス， インコーポレイテッド filed Critical ガーダント ヘルス， インコーポレイテッド
Publication of JP2020504606A publication Critical patent/JP2020504606A/ja
Publication of JP2020504606A5 publication Critical patent/JP2020504606A5/ja
Priority to JP2023060942A priority Critical patent/JP7756676B2/ja
Application granted granted Critical
Publication of JP7300989B2 publication Critical patent/JP7300989B2/ja
Priority to JP2024113220A priority patent/JP2024147684A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/101—DNA polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/107—RNA dependent DNA polymerase,(i.e. reverse transcriptase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/161—Modifications characterised by incorporating target specific and non-target specific sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/164—Methylation detection other then bisulfite or methylation sensitive restriction endonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/131—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/179—Nucleic acid detection characterized by the use of physical, structural and functional properties the label being a nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/514—Detection characterised by immobilisation to a surface characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2019533331A 2016-12-22 2017-12-22 核酸分子を解析するための方法およびシステム Active JP7300989B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023060942A JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム
JP2024113220A JP2024147684A (ja) 2016-12-22 2024-07-16 核酸分子を解析するための方法およびシステム

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662438240P 2016-12-22 2016-12-22
US62/438,240 2016-12-22
US201762512936P 2017-05-31 2017-05-31
US62/512,936 2017-05-31
US201762550540P 2017-08-25 2017-08-25
US62/550,540 2017-08-25
PCT/US2017/068329 WO2018119452A2 (en) 2016-12-22 2017-12-22 Methods and systems for analyzing nucleic acid molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060942A Division JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム

Publications (3)

Publication Number Publication Date
JP2020504606A JP2020504606A (ja) 2020-02-13
JP2020504606A5 JP2020504606A5 (OSRAM) 2021-02-04
JP7300989B2 true JP7300989B2 (ja) 2023-06-30

Family

ID=61006366

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019533331A Active JP7300989B2 (ja) 2016-12-22 2017-12-22 核酸分子を解析するための方法およびシステム
JP2023060942A Active JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム
JP2024113220A Pending JP2024147684A (ja) 2016-12-22 2024-07-16 核酸分子を解析するための方法およびシステム

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023060942A Active JP7756676B2 (ja) 2016-12-22 2023-04-04 核酸分子を解析するための方法およびシステム
JP2024113220A Pending JP2024147684A (ja) 2016-12-22 2024-07-16 核酸分子を解析するための方法およびシステム

Country Status (10)

Country Link
US (7) US11519019B2 (OSRAM)
EP (1) EP3559270A2 (OSRAM)
JP (3) JP7300989B2 (OSRAM)
KR (2) KR20240158369A (OSRAM)
CN (1) CN110325650A (OSRAM)
AU (1) AU2017382439B2 (OSRAM)
CA (1) CA3046007A1 (OSRAM)
IL (2) IL302912A (OSRAM)
MX (1) MX2019007444A (OSRAM)
WO (1) WO2018119452A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509733B1 (en) 2025-04-17 2025-12-30 Inivata Ltd. Methods and systems for detecting a primary disease

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
GB2513024B (en) 2012-02-27 2016-08-31 Cellular Res Inc A clonal amplification method
PL2912468T3 (pl) 2012-10-29 2019-04-30 Univ Johns Hopkins Test papanicolaou pod kątem raka jajnika i endometrium
ES2857908T3 (es) 2013-08-28 2021-09-29 Becton Dickinson Co Análisis masivamente paralelo de células individuales
EP4180535A1 (en) 2015-03-30 2023-05-17 Becton, Dickinson and Company Methods and compositions for combinatorial barcoding
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
KR102522023B1 (ko) 2016-09-26 2023-04-17 셀룰러 리서치, 인크. 바코딩된 올리고뉴클레오티드 서열을 갖는 시약을 이용한 단백질 발현의 측정
WO2018125892A1 (en) * 2016-12-28 2018-07-05 Quest Diagnostics Investments Llc Compositions and methods for detecting circulating tumor dna
CA3059370C (en) 2017-04-12 2022-05-10 Karius, Inc. Methods for concurrent analysis of dna and rna in mixed samples
KR102790050B1 (ko) 2017-06-05 2025-04-04 백톤 디킨슨 앤드 컴퍼니 단일 세포를 위한 샘플 인덱싱
BR112020002555A2 (pt) 2017-08-07 2020-08-11 The Johns Hopkins University métodos e materiais para avaliar e tratar câncer
EP3775198A4 (en) 2018-04-02 2022-01-05 Grail, Inc. METHYLATION MARKERS AND TARGETED METHYLATION PROBE PANELS
WO2019213294A1 (en) 2018-05-03 2019-11-07 Becton, Dickinson And Company High throughput multiomics sample analysis
AU2019310041B2 (en) 2018-07-23 2025-11-20 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
US12178549B2 (en) 2018-10-11 2024-12-31 Seno Medical Instruments, Inc. Optoacoustic image analysis method and system for automatically estimating lesion traits
CN113286881A (zh) 2018-09-27 2021-08-20 格里尔公司 甲基化标记和标靶甲基化探针板
EP4471156A3 (en) 2018-10-01 2025-02-26 Becton, Dickinson and Company Determining 5' transcript sequences
JP7618548B2 (ja) 2018-11-08 2025-01-21 ベクトン・ディキンソン・アンド・カンパニー ランダムプライミングを使用した単一細胞の全トランスクリプトーム解析
WO2020123384A1 (en) 2018-12-13 2020-06-18 Cellular Research, Inc. Selective extension in single cell whole transcriptome analysis
JP2022514010A (ja) * 2018-12-20 2022-02-09 ガーダント ヘルス， インコーポレイテッド 核酸分子の回収率を改善するための方法、組成物、およびシステム
ES2989967T3 (es) 2019-01-23 2024-11-28 Becton Dickinson Co Oligonucleótidos asociados con anticuerpos
CA3127762A1 (en) * 2019-01-25 2020-07-30 Grail, Inc. Detecting cancer, cancer tissue of origin, and/or a cancer cell type
AU2020216438A1 (en) * 2019-01-31 2021-07-29 Guardant Health, Inc. Compositions and methods for isolating cell-free DNA
US12071617B2 (en) 2019-02-14 2024-08-27 Becton, Dickinson And Company Hybrid targeted and whole transcriptome amplification
WO2020176659A1 (en) 2019-02-27 2020-09-03 Guardant Health, Inc. Methods and systems for determining the cellular origin of cell-free dna
JP7441243B2 (ja) * 2019-05-14 2024-02-29 エフ． ホフマン－ラ ロシュ アーゲー 試料分析のための装置および方法
EP3976822A1 (en) 2019-05-31 2022-04-06 Guardant Health, Inc. Methods and systems for improving patient monitoring after surgery
CN120099137A (zh) 2019-07-22 2025-06-06 贝克顿迪金森公司 单细胞染色质免疫沉淀测序测定
CN114269917A (zh) * 2019-08-19 2022-04-01 豪夫迈·罗氏有限公司 用于测序的dna和rna的单管制备
WO2021067484A1 (en) * 2019-09-30 2021-04-08 Guardant Health, Inc. Compositions and methods for analyzing cell-free dna in methylation partitioning assays
CN114729350A (zh) 2019-11-08 2022-07-08 贝克顿迪金森公司 使用随机引发获得用于免疫组库测序的全长v(d)j信息
US11898199B2 (en) 2019-11-11 2024-02-13 Universal Diagnostics, S.A. Detection of colorectal cancer and/or advanced adenomas
WO2021108708A1 (en) * 2019-11-26 2021-06-03 Guardant Health, Inc. Methods, compositions and systems for improving the binding of methylated polynucleotides
CN115151657A (zh) * 2019-12-20 2022-10-04 安可济控股有限公司 用于疾病检测的方法和系统
US11649497B2 (en) 2020-01-13 2023-05-16 Becton, Dickinson And Company Methods and compositions for quantitation of proteins and RNA
GB202000747D0 (en) * 2020-01-17 2020-03-04 Institute Of Cancer Res Monitoring tumour evolution
WO2021155057A1 (en) 2020-01-29 2021-08-05 Becton, Dickinson And Company Barcoded wells for spatial mapping of single cells through sequencing
CA3170345A1 (en) 2020-02-14 2021-08-19 The Johns Hopkins University Methods and materials for assessing nucleic acids
WO2021173719A1 (en) 2020-02-25 2021-09-02 Becton, Dickinson And Company Bi-specific probes to enable the use of single-cell samples as single color compensation control
CA3167633A1 (en) * 2020-02-28 2021-09-02 Pranav Parmjit SINGH Systems and methods for calling variants using methylation sequencing data
WO2021202752A1 (en) * 2020-03-31 2021-10-07 Guardant Health, Inc. Determining tumor fraction for a sample based on methyl binding domain calibration data
WO2021222828A1 (en) 2020-04-30 2021-11-04 Guardant Health, Inc. Methods for sequence determination using partitioned nucleic acids
WO2021231614A1 (en) * 2020-05-12 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University System and method for gene expression and tissue of origin inference from cell-free dna
JP2023526032A (ja) * 2020-05-13 2023-06-20 アキュラーゲン ホールディングス リミテッド セルフリーｄｎａサイズ検出
JP2023526252A (ja) 2020-05-14 2023-06-21 ガーダント ヘルス， インコーポレイテッド 相同組換え修復欠損の検出
EP4150118A1 (en) 2020-05-14 2023-03-22 Becton Dickinson and Company Primers for immune repertoire profiling
WO2021228418A1 (en) 2020-05-15 2021-11-18 Universal Diagnostics, S.L. Methods and systems for identifying methylation biomarkers
IL298458A (en) 2020-05-22 2023-01-01 Aqtual Inc Methods for characterizing cell-free nucleic acid fragments
EP4158055B1 (en) 2020-06-02 2024-03-27 Becton, Dickinson and Company Oligonucleotides and beads for 5 prime gene expression assay
US11530453B2 (en) 2020-06-30 2022-12-20 Universal Diagnostics, S.L. Systems and methods for detection of multiple cancer types
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4407042A3 (en) 2020-07-10 2024-09-18 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
CN111826430A (zh) * 2020-07-24 2020-10-27 扬州大学 一种研究鸡PGCs中lncRNA和组蛋白甲基化酶共调控靶基因的方法
ES3018032T3 (en) * 2020-07-30 2025-05-14 Guardant Health Inc Methods for isolating cell-free dna
WO2022026909A1 (en) 2020-07-31 2022-02-03 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
CN116472348A (zh) * 2020-08-19 2023-07-21 安可济控股有限公司 用于选择性无细胞核酸分析的方法
JP2023540221A (ja) 2020-08-25 2023-09-22 ガーダント ヘルス， インコーポレイテッド バリアントの起源を予測するための方法およびシステム
WO2022073011A1 (en) 2020-09-30 2022-04-07 Guardant Health, Inc. Methods and systems to improve the signal to noise ratio of dna methylation partitioning assays
JP2023547620A (ja) * 2020-10-23 2023-11-13 ガーダント ヘルス， インコーポレイテッド 分配および塩基変換を使用してｄｎａを解析するための組成物および方法
WO2022103857A1 (en) * 2020-11-10 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-cell profiling of chromatin occupancy and rna sequencing
EP4247969A1 (en) 2020-11-17 2023-09-27 Becton, Dickinson and Company Combined analysis of cell-free nucleic acids and single cells for oncology diagnostics
US11739443B2 (en) 2020-11-20 2023-08-29 Becton, Dickinson And Company Profiling of highly expressed and lowly expressed proteins
EP4251765A1 (en) 2020-11-30 2023-10-04 Guardant Health, Inc. Compositions and methods for enriching methylated polynucleotides
US12392771B2 (en) 2020-12-15 2025-08-19 Becton, Dickinson And Company Single cell secretome analysis
EP4267757A1 (en) * 2020-12-23 2023-11-01 Guardant Health, Inc. Methods and systems for analyzing methylated polynucleotides
WO2022174109A1 (en) 2021-02-12 2022-08-18 Guardant Health, Inc. Methods and compositions for detecting nucleic acid variants
WO2022187867A1 (en) * 2021-03-05 2022-09-09 The Trustees Of Columbia University In The City Of New York Methods to analyze methylomes in tumor and plasma cell-free dna
KR20230156364A (ko) 2021-03-05 2023-11-14 가던트 헬쓰, 인크. 분자 반응을 분석하기 위한 방법 및 관련 측면
US20240150825A1 (en) * 2021-03-09 2024-05-09 Claret Bioscience, Llc Methods and compositions for analyzing nucleic acid
US20220344004A1 (en) 2021-03-09 2022-10-27 Guardant Health, Inc. Detecting the presence of a tumor based on off-target polynucleotide sequencing data
WO2022204730A1 (en) 2021-03-25 2022-09-29 Guardant Health, Inc. Methods and compositions for quantifying immune cell dna
US20240191293A1 (en) 2021-03-30 2024-06-13 Resolution Bioscience, Inc. Compositions and methods for simultaneous genetic analysis of multiple libraries
US20240209455A1 (en) * 2021-04-23 2024-06-27 The Translational Genomics Research Institute Analysis of fragment ends in dna
JP2024520422A (ja) 2021-05-28 2024-05-24 ガーダント ヘルス， インコーポレイテッド 循環分子をアッセイするための組成物および方法
WO2022271730A1 (en) 2021-06-21 2022-12-29 Guardant Health, Inc. Methods and compositions for copy-number informed tissue-of-origin analysis
US20250283170A1 (en) * 2021-07-12 2025-09-11 The Trustees Of The University Of Pennsylvania Modified adapters for enzymatic dna deamination and methods of use thereof for epigenetic sequencing of free and immobilized dna
WO2023056065A1 (en) 2021-09-30 2023-04-06 Guardant Health, Inc. Compositions and methods for synthesis and use of probes targeting nucleic acid rearrangements
JP2024540168A (ja) 2021-11-02 2024-10-31 ガーダント ヘルス， インコーポレイテッド 品質管理方法
WO2023086967A1 (en) 2021-11-12 2023-05-19 Guardant Health, Inc. Method of analysis of methylated dna-binding proteins
EP4453241A1 (en) 2021-12-21 2024-10-30 Guardant Health, Inc. Methods and systems for combinatorial chromatin-ip sequencing
EP4453240A1 (en) 2021-12-23 2024-10-30 Guardant Health, Inc. Compositions and methods for detection of metastasis
WO2023147568A2 (en) * 2022-01-28 2023-08-03 Flagship Pioneering Innovations Vi, Llc Compositions and methods for making and using an immortalized library
CA3246524A1 (en) 2022-04-07 2023-10-12 Guardant Health, Inc. TUMOR PRESENCE DETECTION BASED ON THE METHYLATION STATE OF ACELLULAR NUCLEIC ACID MOLECULES
JP2025522763A (ja) 2022-06-30 2025-07-17 ガーダント ヘルス， インコーポレイテッド 異常にメチル化されたｄｎａの富化
JP2025523964A (ja) 2022-07-21 2025-07-25 ガーダント ヘルス， インコーポレイテッド 試料調製により誘発されるメチル化アーチファクトの検出および低減のための方法
WO2024040006A2 (en) * 2022-08-15 2024-02-22 Bioscreening & Diagnostics Llc Ai and ml-based system to predict cancer from epigenetic data
JP2025532567A (ja) 2022-09-16 2025-10-01 ガーダント ヘルス， インコーポレイテッド 可溶性タンパク質を解析するための組成物および方法
EP4594522A2 (en) 2022-09-27 2025-08-06 Guardant Health, Inc. Methods for quantifying immune cell dna
JP2025538871A (ja) 2022-11-15 2025-12-02 ガーダント ヘルス， インコーポレイテッド 非小細胞肺がん（ＮＳＣＬＣ）患者の薬物応答または死亡もしくはがん進行までの時間を、循環腫瘍ＤＮＡ（ｃｔＤＮＡ）から、ベースラインｃｔＤＮＡレベルおよびｃｔＤＮＡレベルの経時的な縦断的変化の両方からのシグナルを利用して予測する方法
WO2024137682A1 (en) 2022-12-21 2024-06-27 Guardant Health, Inc. Detecting homologous recombination deficiences based on methylation status of cell-free nucleic acid molecules
EP4638781A2 (en) 2022-12-22 2025-10-29 Guardant Health, Inc. Methods involving methylation preserving amplification with error correction
EP4638782A2 (en) 2022-12-22 2025-10-29 Guardant Health, Inc. Integrated targeted and whole genome somatic and dna methylation sequencing workflows
WO2024151825A1 (en) 2023-01-11 2024-07-18 Guardant Health, Inc. Joint modeling of longitudinal and time-to-event data to predict patient survival
EP4655416A1 (en) 2023-01-25 2025-12-03 Guardant Health, Inc. Nucleic acid methylation profiling method
WO2024186768A1 (en) * 2023-03-07 2024-09-12 Guardant Health, Inc. Hybrid ssdna- and dsdna-ngs library preparation methods
US20250101522A1 (en) 2023-04-12 2025-03-27 Guardant Health, Inc. Brca1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy
WO2024229143A1 (en) 2023-05-01 2024-11-07 Guardant Health, Inc. Quality control method for enzymatic conversion procedures
WO2024229433A1 (en) 2023-05-03 2024-11-07 Guardant Health, Inc. Methods for analysis of dna methylation
WO2024233502A1 (en) 2023-05-05 2024-11-14 Guardant Health, Inc. Cell-free dna blood-based test for cancer screening
WO2024259251A1 (en) 2023-06-15 2024-12-19 Guardant Health, Inc. Method for hrd detection in targeted cfdna samples using de novo mutational signatures
WO2024264065A1 (en) 2023-06-23 2024-12-26 Guardant Health, Inc. Methods and compositions for quantifying immune cell nucleic acids
WO2025007034A1 (en) 2023-06-29 2025-01-02 Guardant Health, Inc. Methods for determining surveillance and therapy for diseases
WO2025007038A1 (en) 2023-06-30 2025-01-02 Guardant Health, Inc. Methods for early detection of cancer
WO2025019254A1 (en) 2023-07-14 2025-01-23 Guardant Health, Inc. Classification of breast tumors using dna methylation from liquid biopsy
WO2025019370A1 (en) * 2023-07-14 2025-01-23 Natera, Inc. Methods for assaying circulating tumor dna
WO2025019297A1 (en) 2023-07-14 2025-01-23 Guardant Health, Inc. Classification of colorectal tumors using dna methylation from liquid biopsy
WO2025024497A1 (en) 2023-07-24 2025-01-30 Guardant Health, Inc. Significance modeling of clonal-level target variants using methylation detection
WO2025029475A1 (en) 2023-07-28 2025-02-06 Guardant Health, Inc. Methods to enrich nucleotide variants by negative selection
US20250201344A1 (en) 2023-07-28 2025-06-19 Guardant Health, Inc. Methods and systems for identifying an origin of a variant
WO2025029751A1 (en) 2023-07-31 2025-02-06 Guardant Health, Inc. Methods and systems for identifying tumor origin
WO2025038399A1 (en) 2023-08-11 2025-02-20 Guardant Health, Inc. Methylated enrichment methods for single-molecule genetic and epigenetic sequencing
WO2025059338A1 (en) 2023-09-12 2025-03-20 Guardant Health, Inc. Methods for analyzing nucleic acids using sequence read family size distribution
WO2025064706A1 (en) 2023-09-19 2025-03-27 Guardant Health, Inc. Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
WO2025064489A1 (en) 2023-09-20 2025-03-27 Guardant Health, Inc. Systems and methods for real world evidence database data integration
WO2025072084A1 (en) * 2023-09-25 2025-04-03 Foundation Medicine, Inc. Updating records based on consensus annotations of genetic variants
WO2025072467A1 (en) 2023-09-29 2025-04-03 Guardant Health, Inc. Genotyping cyp2d6
US20250250638A1 (en) 2023-10-06 2025-08-07 Guardant Health, Inc. Genomic and methylation biomarkers for prediction of copy number loss / gene deletion
WO2025085784A1 (en) 2023-10-18 2025-04-24 Guardant Health, Inc. Genomic and methylation biomarkers for determining patient risk of heart disease and novel genomic and epigenomic drug targets to decrease risk of heart disease and/or improve patient outcome after myocardial infarction or cardiac injury
WO2025090956A1 (en) 2023-10-26 2025-05-01 Guardant Health, Inc. Methods for detecting nucleic acid variants using capture probes
WO2025090954A1 (en) 2023-10-26 2025-05-01 Guardant Health, Inc. Methods for detecting nucleic acid variants
WO2025106263A1 (en) 2023-11-15 2025-05-22 Guardant Health, Inc. Joint modeling of longitudinal and time-to-event data to predict patient survival
WO2025106837A1 (en) 2023-11-15 2025-05-22 Guardant Health, Inc. Tumor fraction and outcome association in a real-world non-small cell lung cancer (nsclc) cohort using a methylation-based circulating tumor dna (ctdna) assay
WO2025106796A1 (en) 2023-11-15 2025-05-22 Guardant Health, Inc. Non-small cell lung cancer (nsclc) histology classification using dna methylation data captured from liquid biopsies
WO2025106275A1 (en) 2023-11-15 2025-05-22 Guardant Health, Inc. Minimum residual disease (mrd) detection in early stage cancer using urine
WO2025137620A1 (en) 2023-12-21 2025-06-26 Guardant Health, Inc. Methods for high quality and high accuracy methylation sequencing
WO2025160433A1 (en) 2024-01-24 2025-07-31 Guardant Health, Inc. Methods for analyzing sequencing reads
WO2025207817A1 (en) 2024-03-26 2025-10-02 Guardant Health, Inc. Method of determining the likelihood of a disease by combining biomarkers and imaging
US20250308636A1 (en) 2024-03-27 2025-10-02 Guardant Health, Inc. Inferring cnvs from the distribution of molecules in hyper partition
WO2025207925A1 (en) 2024-03-28 2025-10-02 Guardant Health, Inc. Methods for methylation enrichment using preferential ligation of adapters
WO2025208044A1 (en) 2024-03-28 2025-10-02 Guardant Health, Inc. Methods for cancer detection using molecular patterns
WO2025212664A1 (en) 2024-04-01 2025-10-09 Guardant Health, Inc. Small variant calling with error-rate based model
WO2025235602A1 (en) 2024-05-07 2025-11-13 Guardant Health, Inc. Predictive, prognostic signatures for immuno-oncology using liquid biopsy
WO2025235889A1 (en) 2024-05-10 2025-11-13 Guardant Health, Inc. Methods involving multiplexed pooled pcr
US20250364077A1 (en) 2024-05-23 2025-11-27 Guardant Health, Inc. Generalized probabilistic generative modeling method for analysis of tumor methylated molecules in target capture regions
WO2025250544A1 (en) 2024-05-31 2025-12-04 Guardant Health, Inc. Methods for analyzing chromatin architecture in tissue to boost detection of cancer associated signals in cell-free dna
US12467087B1 (en) 2024-06-25 2025-11-11 Guardant Health, Inc. Sequencing methods with partitioning

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015159292A2 (en) 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2016115530A1 (en) 2015-01-18 2016-07-21 The Regents Of The University Of California Method and system for determining cancer status

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20030017081A1 (en) 1994-02-10 2003-01-23 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
WO2003046146A2 (en) 2001-11-28 2003-06-05 Applera Corporation Compositions and methods of selective nucleic acid isolation
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) * 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
WO2010037001A2 (en) * 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
US20130157266A1 (en) * 2009-03-15 2013-06-20 Ribomed Biotechnologies, Inc. Abscription based molecular detection of dna methylation
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
EP4328321A3 (en) * 2010-10-22 2024-05-29 Cold Spring Harbor Laboratory Varietal counting of nucleic acids for obtaining genomic copy number information
EP4574995A3 (en) * 2011-12-13 2025-10-15 Oslo Universitetssykehus HF Methods and kits for detection of methylation status
WO2013142389A1 (en) * 2012-03-20 2013-09-26 University Of Washington Through Its Center For Commercialization Methods of lowering the error rate of massively parallel dna sequencing using duplex consensus sequencing
WO2013184930A2 (en) * 2012-06-06 2013-12-12 Trustees Of Princeton University Dna barcoding of designer mononucleosome and chromatin array libraries for the profiling of chromatin readers, writers, erasers, and modulators thereof
JP2015521862A (ja) * 2012-07-13 2015-08-03 セクエノム， インコーポレイテッド 非侵襲性の出生前診断に有用な母体サンプル由来の胎児核酸のメチル化に基づく富化のためのプロセスおよび組成物
ES2769241T5 (es) 2012-09-04 2023-05-30 Guardant Health Inc Sistemas y métodos para detectar variación en el número de copias
US9732390B2 (en) 2012-09-20 2017-08-15 The Chinese University Of Hong Kong Non-invasive determination of methylome of fetus or tumor from plasma
US10612088B2 (en) 2013-03-14 2020-04-07 The Broad Institute, Inc. Massively multiplexed RNA sequencing
US20160047001A1 (en) * 2013-04-08 2016-02-18 Carmel-Haifa University Economic Corporation Ltd. Sept4/ARTS AS A TUMOR SUPPRESSOR IN THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF HEPATIC DISORDERS
EP2805769A1 (en) * 2013-05-24 2014-11-26 European Molecular Biology Laboratory Methods for nano-scale single cell analysis
KR102373647B1 (ko) 2013-10-21 2022-03-11 베리나타 헬스, 인코포레이티드 사본수 변동을 결정함에 있어서 검출의 감수성을 향상시키기 위한 방법
WO2016015058A2 (en) 2014-07-25 2016-01-28 University Of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
CN107075730A (zh) 2014-09-12 2017-08-18 利兰·斯坦福青年大学托管委员会 循环核酸的鉴定及用途
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
US10844428B2 (en) * 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
US20190085406A1 (en) 2016-04-14 2019-03-21 Guardant Health, Inc. Methods for early detection of cancer
US11702702B2 (en) * 2016-04-15 2023-07-18 Predicine, Inc. Systems and methods for detecting genetic alterations
JP2019515674A (ja) * 2016-04-19 2019-06-13 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝的解析および他の適用のための固定化ベースのシステムおよび方法
EP4425178A3 (en) 2016-05-03 2024-12-18 University Health Network Methods of capturing cell-free methylated dna and uses of same
AU2017290237B2 (en) * 2016-06-30 2020-10-22 GRAIL, Inc Differential tagging of RNA for preparation of a cell-free DNA/RNA sequencing library
JP7448310B2 (ja) 2016-07-06 2024-03-12 ガーダント ヘルス， インコーポレイテッド セルフリー核酸のフラグメントームプロファイリングのための方法
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
WO2019010564A1 (en) 2017-07-12 2019-01-17 University Health Network DETECTION AND CLASSIFICATION OF CANCER USING METHYLOME ANALYSIS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015159292A2 (en) 2014-04-14 2015-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2016115530A1 (en) 2015-01-18 2016-07-21 The Regents Of The University Of California Method and system for determining cancer status

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Applications in Plant Sciences，2014年，Vol. 2: 1400064，p. 1-6
Genome Research，2010年，Vol. 20，p. 1719-1729

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509733B1 (en) 2025-04-17 2025-12-30 Inivata Ltd. Methods and systems for detecting a primary disease

Also Published As

Publication number Publication date
KR20240158369A (ko) 2024-11-04
US12312634B2 (en) 2025-05-27
WO2018119452A2 (en) 2018-06-28
CN110325650A (zh) 2019-10-11
US11519019B2 (en) 2022-12-06
US12359245B2 (en) 2025-07-15
US20250154558A1 (en) 2025-05-15
JP2020504606A (ja) 2020-02-13
KR102723226B1 (ko) 2024-10-30
IL302912A (en) 2023-07-01
US20250171826A1 (en) 2025-05-29
US20240279714A1 (en) 2024-08-22
EP3559270A2 (en) 2019-10-30
KR20190095410A (ko) 2019-08-14
AU2017382439B2 (en) 2024-08-08
JP7756676B2 (ja) 2025-10-20
CA3046007A1 (en) 2018-06-28
MX2019007444A (es) 2019-08-16
US20230332206A1 (en) 2023-10-19
US20240409979A1 (en) 2024-12-12
AU2017382439A1 (en) 2019-06-20
US20240409980A1 (en) 2024-12-12
BR112019012958A2 (pt) 2019-11-26
US20190390253A1 (en) 2019-12-26
JP2024147684A (ja) 2024-10-16
IL267424A (en) 2019-08-29
US11952616B2 (en) 2024-04-09
US12428670B2 (en) 2025-09-30
WO2018119452A3 (en) 2018-08-09
JP2023089062A (ja) 2023-06-27

Similar Documents

Publication Publication Date Title
JP7756676B2 (ja) 核酸分子を解析するための方法およびシステム
JP7573536B2 (ja) 無細胞ｄｎａを単離するための組成物および方法
JP2024056984A (ja) エピジェネティック区画アッセイを較正するための方法、組成物およびシステム
JP2024523401A (ja) コピー数情報に基づく組織起源分析のための方法および組成物
JP2023524681A (ja) 分配された核酸を使用した配列決定のための方法
US20250308629A1 (en) Small variant calling with error-rate based model
US20250308636A1 (en) Inferring cnvs from the distribution of molecules in hyper partition
US20250201344A1 (en) Methods and systems for identifying an origin of a variant
US20250218587A1 (en) Methods and systems for identifying tumor origin
US20250243550A1 (en) Minimum residual disease (mrd) detection in early stage cancer using urine
BR112019012958B1 (pt) Métodos e sistemas para análise de moléculas de ácido nucleico

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230620

R150 Certificate of patent or registration of utility model

Ref document number: 7300989

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150